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Background. Mannan-binding lectin (MBL) is involved in the development of diabetic nephropathy. MBL is a part of the innate
immune system where it can activate the complement system. Serum MBL level predicts later renal impairment in diabetes
patients. Direct involvement of MBL in the development of diabetic kidney disease is observed in one animal strain. However,
this involvement may diﬀer among the animal strains. We thus examined the impact of the genetic background on the role of
MBL in diabetic nephropathy. Materials/Methods. C57BL/6JBomTac and 129S6/SvEvTac mice were compared. In both strains,
experimental type 1 diabetes was induced in wild-type (WT) and MBL-knockout (MBL-KO) mice by streptozotocin. Nondiabetic
WT and MBL-KO mice were used as controls. We tested if MBL modiﬁed the diabetes-induced kidney changes by two-way
ANOVA allowing for interaction. Results. MBL aggravated diabetes-induced kidney growth and glomerulus enlargement in
C57BL/6JBomTac mice. MBL did not modify diabetes eﬀects on glomerular basement membrane thickness or mesangial volume
in any strain. Diabetes-induced changes in renal gene transcription of growth factors and matrix components were unaﬀected
by MBL. Conclusions. Strain-speciﬁc MBL eﬀects were found on downstream diabetic kidney changes. This emphasizes the
importance of genetic background in this model of diabetic complications.
1.Introduction
Diabetic nephropathy is the most common cause of end-
stage renal disease in many Western countries [1–5]. The
cumulative incidence of diabetic nephropathy is about one-
third in diﬀerent diabetic populations [6–10]. Although
the incidence has fallen during the last decades, better
treatment and identiﬁcation of high-risk patients are still
needed [11]. An unknown genetic predisposition to diabetic
vascular complications is plausible since not all patients at
risk will develop diabetic nephropathy and because diabetic
nephropathy clusters in families [12, 13].
The complement system is an inﬂammation activating
part of the innate immune system and appears to be impor-
tant for vascular damage in the heart and in the kidneys of
diabetic patients [14]. Mannan-binding lectin (MBL) is a
recognition molecule and the ﬁrst step of the lectin pathway
of complement activation. Interindividual variations in MBL
serum level may account for some predisposition to vascular
late complications to diabetes. The association between high
MBL and renal dysfunction is well-described in type 1
diabetes [15–17]. Furthermore, the MBL level in the early
stage of type 1 diabetes predicts the risk of future renal
dysfunction [18]. In type 2 diabetes, the association between2 Experimental Diabetes Research
MBL and renal function is less documented. The MBL
level tends to predict renal impairment in type 2 diabetes
and combined with C-reactive protein the prognostic value
of MBL level reaches statistical signiﬁcance [19]. We have
previouslystudiedtheeﬀectsofMBLonearlydiabetickidney
disease by MBL-KO mice backcrossed for six generations on
the C57BL/6JBomTac background [20]. In the present study
we examined the role of MBL in animals backcrossed for 12
generations which ensured a more homogeneous group of
animals. MBL interaction with eﬀects of diabetes may diﬀer
between the models, for example, between genetic back-
grounds. As the C57BL/6JBomTac strain is relatively more
resistant to diabetic kidney changes than the 129S6/SvEvTac
strain, we compared these strains in the present study [21].
In this setup, we evaluated the genetic impact on kidney
changes after the induction of experimental type 1 diabetes.
Nondiabetic WT and nondiabetic MBL-KO animals were
used as controls.
2. Methods
2.1. Animals. We used female C57BL/6JBomTac and female
129S6/SvEvTac mice. Both WT and MBL-KO mice were
included in both strains (MBL-KO mice lack both murine
forms of MBL, MBL-A, and MBL-C). The development
of MBL-KO animals have previously been described [22].
In brief, MBL double-knockout mice were developed on
a mixed C57BL/6×Sv129EvSv background and later back-
crossed onto both C57BL/6JBomTac and to 129S6/SvEvTac
background. WT animals of both strains were purchased
from Taconic (Ry, Denmark). MBL-KO animals came from
our own breeding (backcrossed 12 generations or more
on C57BL/6JBomTac or 129S6/SvEvTac, resp.). At study
start, C57BL/6JBomTac animals were 10 weeks old and
129S6/SvEvTac animals were 11 weeks old. Diabetes was
induced by streptozotocin (STZ) (Sigma-Aldrich Corp., St.
Louis, MO, USA) as described below. All C57BL/6JBomTac
animals were sacriﬁced 12 weeks after diabetes induction
and all 129S6/SvEvTac animals were sacriﬁced 14 weeks
after diabetes induction. The varying diabetes duration is
explained by diﬀerent rates of responses to STZ (6 weeks
in C57BL/6JBomTac animals and 4 weeks in 129S6/SvEvTac
animals) and coincident time of sacriﬁce. The animals
were housed 5 to 7 animals per cage in a room with a
12:12-hour artiﬁcial light cycle (light 7.00h to 19.00h.),
at e m p e r a t u r eo f2 1 ±1◦C, and a humidity of 55±5%. The
animals had free access to standard chow (Altromin #1324;
Lage, Germany) and tap water throughout the experiment.
Food consumption was determined at group basis at the end
of the study. Blood glucose was measured in tail-capillary
blood as described below. Body weight and blood glucose
were measured weekly throughout the study. Animals with
signs of illness (n = 2, please see section 2.2), ketonuria
(n = 0), and more than 10% weight loss (n = 0) were
excluded. The study complied with the Danish regulations
for care and use of laboratory animals.
2.2. Design. Four groups were made from both strains;
diabetes (yes/no) and MBL-KO (yes/no). In this manner
C57BL/6JBomTac animals were randomly divided into four
groups: (1) control WT (n = 7), (2) diabetic WT (n = 7), (3)
control MBL-KO (n = 6), and (4) diabetic MBL-KO (n = 6).
Likewise, 129S6/SvEvTac mice were randomly divided into
four groups: (1) control WT (n = 5), (2) diabetic WT (n =
6), (3) control MBL-KO (n = 5), and (4) diabetic MBL-KO
(n = 6).
Two C57BL/6JBomTac animals were excluded: one from
the control MBL-KO group because of hydronephrosis and
one from the diabetic MBL-KO group because of severe
polycystic kidney disease. Serum from one 129S6/SvEvTac
control MBL-KO mouse was lost during preparation.
2.3. Induction of Diabetes. Diabetes was induced by ﬁve
intraperitonealSTZ-injectionsonﬁveconsecutivedaysusing
doses of 45mg/kg body weight. If not diabetic after these
injections, the animals were re-injected intra-peritoneally
with doses of 45mgSTZ/kg body weight until diabetes was
achieved. Animals were considered as diabetic when blood
glucose was above 18mmol/L.
2.4. Determination of Blood Glucose and Urinalysis. Blood
glucose was measured in tail-capillary blood by Contour
(BayerDiabetesCare,KongensLyngby,Denmark).Urinewas
tested for glucose and ketone bodies by Combur5 Test D
(Roche Diagnostics GmbH, Mannheim, Germany).
2.5. Sacriﬁce and Samples for Examination. At the end of the
study, urine was collected in metabolic cages individually
and stored at −20◦C until assayed. At sacriﬁce, the animals
were anesthetized by an intraperitoneal dose of 0.5mg/g
body weight ketamine and 0.2mg/g body weight xylazine
(Ketaminol Vet and Narcoxyl Vet, resp., Intervet, Skovlunde,
Denmark). Nonfasting blood samples were drawn in hep-
arinized capillary tubes from the retroorbital venous plexus,
and serum was separated. Serum samples were stored at
−20◦C until analyzed. Kidneys, liver, and heart from all
animals were dissected and weighed. The poles and the
middle pieces of the right kidneys were snap-frozen in liquid
nitrogen for later mRNA analyses and stored at −80◦C. Left
kidney was ﬁxed in a mixture of 3% formaldehyde and
1% glutaraldehyde, cut in 1mm slices and 2 slices were
randomlysampled.Fromthesetwoslices,ﬁverandompieces
were area-sampled and embedded in Epon 825 for electron
microscopy, whereas the remaining tissue was embedded in
paraﬃn for light microscopy. Morphological methods are
described below.
2.6. Determination of Urinary Albumin Excretion (UAE) and
Creatinine Clearance. Albumin was determined in urine
collections by Mouse Albumin ELISA Quantiﬁcation Kit
(BethylLaboratories,Inc.,Montgomery,TX,USA)according
to the manufacturer’s instructions. Creatinine was measured
by high-performance liquid chromatography as previously
described [23].Experimental Diabetes Research 3
2.7. Estimation of Glomerular Volume. The kidney slices
embedded in paraﬃnw e r ec u ti n1 5 μm thick sections on
a rotatory microtome and stained with Periodic acid-Schiﬀ.
In these sections, blinded estimation of glomerular volume
fraction was performed by point counting (CAST software,
Olympus, Copenhagen, Denmark). Glomerulus-to-kidney
ratiowascalculatedfromtheseestimatesbasedon50ormore
glomeruli per section.
2.8. Estimation of Glomerular Basement Membrane Thickness,
Mesangial Fraction and Total Mesangial Volume. These esti-
mates were examined by electron microscopy as previously
described [20]. In brief, the ﬁve small pieces embedded in
Epon825werecutinultrathinsectionsonanRMCMT-7000
Ultramicrotome (Boeckeler Instruments Inc., AZ, USA).
Electron microscopy images (CM10, Phillips, Eindhoven,
Holland) were recorded with a Kodak megaplus 1.6i digital
camera applying a multiple-Image alignment system onto a
monitor.
2.9. Quantitative RT-PCR. The quantiﬁcations by RT-PCR
were performed as previously described [20]. In brief, total
cellular RNA was extracted from renal cortical tissue by a
6100 Nucleic Acid PrepStation (Applied Biosystems, Foster
City,CA,USA).ThequalityofribosomalRNAwasestimated
by agarose gel. Reverse transcription from RNA to DNA
was performed with a Multiscribe Reverse Transcriptase kit
(Applied Biosystems). The polymerase chain reaction was
performed in triplicates of each sample in wells containing
RNA, TaqMan Universal PCR MasterMix and amplifying
primers purchased from Applied Biosystems. Ribosomal 18S
was used as housekeeping gene. Liver RNA was used as
negative controls. Data were analyzed with the ABI Prism
7000 Sequence Detector Software from Applied Biosystems.
The relative quantiﬁcation of target gene was calculated as
described in the Users Bulletin 2, 1997 from Perkin-Elmer
(Perkin-Elmer Cetus, Norwalk, CT, USA) [24].
2.10. Statistical Analysis. The study was designed as a 2 times
2factorialexperimentandthusanalyzedbytwo-wayANOVA
allowing for interaction. First, we tested if the diabetes eﬀect
was modiﬁed by MBL (eﬀect modiﬁcation or interaction). If
interaction between diabetes and MBL was found, we tested
thehypothesisthatthetwonondiabeticgroupsdidnotdiﬀer.
Only if we could accept the hypothesis of no interaction,
we could test the hypothesis that no isolated eﬀect of MBL
and diabetes could be found. The Kruskal-Wallis equality
of population rank test was used if normality and equal
variances could not be achieved by transformation and these
data are therefore not evaluated for interaction, isolated
MBL eﬀect, or diabetic eﬀect. All RT-PCR measurements
were transformed by the natural logarithm for comparisons
as ratios rather than diﬀerences. Unless otherwise stated,
all data are expressed as mean (95% conﬁdence interval),
number as stated above in, except when other numbers are
given.P<0.05wasconsideredsigniﬁcant.Statisticalanalyses
were performed by STATA 11.0 for Microsoft Windows.
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Figure 1: Kidney-to-body weight ratio. Kidney-to-body weight
ratio by mouse strain: WT, diabetes WT (d-WT), MBL-KO (KO),
and diabetes MBL-KO (d-KO). (a) C57BL/6JBomTac animals with
mean indicated by “.” (b) 129S6/SvEvTac animals with median
indicated by “” (median presented as untransformed data showed
unequal variances among groups). Test statistics are indicated in
plot area when signiﬁcant. PMBL×D: interaction between MBL and
diabetic eﬀects; PD: diabetic change.
3. Results
3.1. Animal Characteristics. Body weights of the animals
are presented in Table 1. To best describe the overall level
throughout this study, the diabetic groups were compared
estimating blood glucose as area under the curve (days times
glucose concentration). In both strains, diabetic animals had
equal levels of blood glucose (Table 1). Glucose levels at start
and end are listed in Table 1.
3.2. Kidney Morphology. The diabetes-induced kidney hy-
pertrophy signiﬁcantly depended on MBL in C57BL/
6JBomTac animals (interaction between diabetes and MBL,
P<0.001). Diabetes induced a 29% (15;45) larger
increase in kidney-to-body weight ratio in WT animals (41%
increase) compared with MBL-KO animals (9% increase)
(Figure 1(a)). Kidney-to-body weight ratio was 11% (2;21)
larger in nondiabetes WT animals compared with nondia-
betic MBL-KO animals (P = 0.02). In 129S6/SvEvTac ani-
mals, no interaction was found and we therefore continued
testing for an isolated diﬀerence between MBL-KO and WT
animals and between diabetes and control animals (please
refer to Methods Section for further details). Accordingly,
we found that diabetic animals had larger kidney-to-body
weight ratio than the control animals (59% (47;72), P<
0.001). MBL deﬁciency had no eﬀect on kidney weight
(Figure 1(b)).
MBL modiﬁed the diabetes-induced glomerulus enlarge-
ment in C57BL/6JBomTac animals (Figure 2(a)). Due to4 Experimental Diabetes Research
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Figure 2: Glomerular volume. Total glomerular volume by mouse strain: WT, diabetes WT (d-WT), MBL-KO (KO), and diabetes MBL-
KO (d-KO) and representative images from each group (total magniﬁcation 1855x). (a) C57BL/6JBomTac animals with mean indicated by
“.” (b) 129S6/SvEvTac animals with mean indicated by “.” Test statistics are indicated in plot area when signiﬁcant. PMBL×D: interaction
between MBL and diabetic eﬀects.Experimental Diabetes Research 5
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Figure 3: Urinary albumin excretion. Urinary albumin excretion
(UAE) by mouse strain: WT, diabetes WT (d-WT), MBL-KO
(KO),anddiabetesMBL-KO(d-KO).(a)C57BL/6JBomTacanimals
with mean indicated by “.” (b) 129S6/SvEvTac animals with
“” indicating the median (median presented as untransformed
data showed unequal variances among groups). Test statistics are
indicated in plot area when signiﬁcant. PD: diabetic change.
diabetes, total glomerulus volume increased 40% (7;84)
more in WT animals compared to MBL-KO animals (P =
0.02).NodiﬀerenceswereseeninthecontrolWTandcontrol
MBL-KO groups. In 129S6/SvEvTac animals no signs of
interaction and no diabetic changes were seen, nor were any
consequencesofMBLknockoutfound.Basementmembrane
thickness and mesangium-to-glomerulus volume fraction
did not diﬀer among groups in both strains (data not
shown).
3.3. UAE and Creatinine Clearance. The diabetes-induced
increase in UAE was not modiﬁed by MBL in any of the
strains. Diabetic C57BL/6JBomTac animals showed a 3.0-
fold (1.8;5.0) increase in UAE compared with nondiabetic
animals (P<0.001) (Figure 3(a)). Diabetes induced an 8.9-
fold increase in UAE in 129S6/SvEvTac animals compared
with nondiabetic controls (4.6;17.4), P<0.001. In both
strains there were no eﬀect of MBL deﬁciency (Figure 3(b)).
Creatinine clearance did not diﬀer among groups in
C57BL/6JBomTac animals (Figure 4(a)). In the 129S6/
SvEvTac animals, no eﬀectmodication between diabetes and
MBL was found on creatinine clearance and creatinine
clearance was not altered in MBL-deﬁcient animals or in
diabetes (Figure 4(b)).
3.4. Renal Gene Transcription. Gene transcripts involved in
diabetickidneychangesweremeasuredbyRT-PCR(Table 2).
MBL did not interact with the diabetes-induced changes on
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Figure 4: Creatinine clearance. Creatinine clearance by mouse
strain: WT, diabetes WT (d-WT), MBL-KO (KO), and diabetes
MBL-KO (d-KO). (a) C57BL/6JBomTac animals with median
indicated by “” (median presented as data could not be ﬁtted
to normality). (b) 129S6/SvEvTac animals with “” indicating the
mean. In 129S6/SvEvTac animals, creatinine clearance could not
be estimated in two animals because of technical issues (both
controlMBL-KOanimals)andintwoanimalsbecauseoflostserum
(one control MBL-KO animal and one diabetic MBL-KO animal).
No statistical signiﬁcance was found on interaction between MBL
and diabetic eﬀects, or on diabetic change, or on impact of MBL
deﬁciency.
the tested gene transcripts. In both strains, transcription of
growth factors important for sclerotic changes was upregu-
lated in diabetes, that is, transforming growth factor β and
connective tissue growth factor. Genes for matrix proteins
were also transcribed at higher levels in diabetes (i.e.,
ﬁbronectin and collagen IVα1), whereas vascular endothelial
growth factor-A mRNA expression was downregulated in
both strains.
Connective tissue growth factor, ﬁbronectin and vas-
cular endothelial growth factor receptor 2 transcriptions
were downregulated in MBL-KO animals compared with
WT in C57BL/6JBomTac animals. In 129S6/SvEvTac MBL-
KO animals, transcriptions of transforming growth factor
β, collagen IVα1, and vascular endothelial growth factor
receptor 2 were upregulated compared with WT animals.
4. Discussion
In the present study causal involvement of MBL in the
development of key characteristic diabetic kidney changes
were demonstrated. We found that growth of kidneys and
glomeruli in diabetes were signiﬁcantly modiﬁed by MBL
in agreement with previous ﬁndings in MBL-KO animals
backcrossed for only six generations [20]. As hypothesized,6 Experimental Diabetes Research
Table 1: Body weight and blood glucose.
Group ANOVA
Strain WT d-WT KO d-KO PMBL×D PD PMBL Knockout
Body weight (g)
C57BL/6JBomTac, start 21.1
(19.8;22.5)
20.8
(19.4;22.2)
19.6
(18.0;21.2)
20.7
(19.1;22.3) NS NS NS
C57BL/6JBomTac, end 25.3
(24.2;26.4)
22.4
(21.3;23.5)
25.3
(24.0;26.6)
22.2
(20.9;23.5) NS <0.001 NS
129S6/SvEvTac, start 20.9
(19.5;22.6)
20.6
(19.4;21.8)
18.2
(16.8;19.5)
17.7
(16.5;19.0) NS NS <0.001
129S6/SvEvTac, end 25.7
(23.7;27.7)
23.7
(21.8;25.5)
22.4
(20.3;24.4)
20.8
(18.9;22.6) NS 0.06 0.003
Student’s t-test
PWT versus KO Pd-WT versus d-KO
Blood glucose
(mmol/L)
C57BL/6JBomTac, start 6.3
(5.4;7.3)
5.9
(4.9;6.8)
6.1
(4.9;7.2)
7.5
(6.4;8.7) NS 0.03
C57BL/6JBomTac, end 6.0
(2.8;9.2)
20.7
(17.5;23.9)
6.2
(2.4;10.0)
22.0
(18.2;25.7) NS NS
C57BL/6JBomTac, area
under the curve NS
129S6/SvEvTac, start 6.2
(5.3;7.0)
6.8
(6.1;7.6)
6.3
(5.5;7.1)
7.2
(6.4;7.9) NS NS
129S6/SvEvTac, end 6.2
(4.3;8.2)
20.4
(18.6;22.2)
6.4
(4.5;8.3)
16.8
(15.0;18.6) NS 0.007
129S6/SvEvTac, area
under the curve NS
Body weight and blood glucose by strain at start and end of study in wild-type (WT), diabetes WT (d-WT), MBL knockout (KO), and diabetes KO (d-KO).
Values indicate mean (95% conﬁdence interval).
Comparisons were made with ANOVA (body weight) and Student’s t-test (blood glucose).
PMBL×D: interaction between diabetes and MBL.
PD: diabetic versus nondiabetic animals.
PMBL: MBL knockout versus WT animals.
PWT versus KO: wild-type versus knockout.
Pd-WT versus d-KO: diabetic wild-type versus diabetic knockout; NS: P > 0.05.
the role of MBL was dependent on the genetic background
of the mice. This indicates an important genetically deter-
mined diﬀerence in susceptibility to MBL regarding the
development of diabetic kidney disease. Previous studies
characterized diabetic kidney changes in various mouse
models and found great inﬂuence of the genetic background
[25, 26]. The ability to mimic the diﬀerent characteristics
of human diabetic nephropathy varies between models [21].
Accordingly, STZ diabetes in C57BL/6JBomTac animals, and
to some extent also in 129S6/SvEvTac animals, imitates the
structural kidney changes in human diabetes better than
functional alternations in UAE [25, 26]. In the present
report we ﬁnd that STZ diabetes induces kidney changes in
accordance with diabetic nephropathy in both strains. The
models limitations to resemble functional diabetic kidney
changes may account for the inability to ﬁnd the association
between MBL and diabetes-induced elevated UAE, which
has been reported in numerous human studies [15, 17–
19, 27, 28]. In the present study, also a higher kidney-to-
body weight ratio was found in control C57BL/6JBomTac
MBL-KO animals compared with control WT animals.
Diﬀerent growth rates in KO compared with WT animals
may account for part of this. We have previously shown a
trend of MBL to modify the diabetes-induced increases in
glomerulus basement membrane thickness and mesangial
volume [20]. However, this could not be repeated in the
present study, most likely due to longer diabetes duration
and to the more genetically similar group with animals
backcrossed for more than 12 generations. Diabetes-induced
changes in renal gene transcription of known key mediators
were not found to be modiﬁed by MBL in this study.
The time of determination might inﬂuence the outcome
of these measurements. We found a decreased vascular
endothelial growth factor A transcription in both mouse
strains at an early stage of diabetic kidney disease. Diﬀering
reports have been published on vascular endothelial growth
factor levels. Though most studies ﬁnd an upregulation
of vascular endothelial growth factor, we have consistently
found downregulation of vascular endothelial growth factor
A in STZ-diabetic mice after diabetes durations of 8 to 12
weeks [29–32]. Diﬀering sample site and diabetes duration
may explain these observations.
The importance of genetic composition regarding sus-
ceptibility to diabetic nephropathy is illustrated from obser-
vations in twins.Seaquistet al.described a strong association
between genetic composition and risk of end-stage renalExperimental Diabetes Research 7
Table 2: Renal gene expression.
ANOVA
mRNA, strain PMBL×D PD PMBL knockout
TGF-β, C57BL/6JBomTac NS 2.3-fold (1.7;3.1), P<0.001 NS
TGF-β, 129S6/SvEvTac NS 2.5-fold (1.8;3.6), P<0.001 44% (2;104), P = 0.04
CTGF, C57BL/6JBomTac NS 33% (9;64), P<0.008 −34% (−19;−46), P<0.001
CTGF, 129S6/SvEvTac NS 2.2-fold (1.5;3.1), P<0.001 NS
Fibronectin,
C57BL/6JBomTac NS 2.6-fold (1.9;3.7), P<0.001 −30% (−2;−50), P = 0.04
Fibronectin, 129S6/SvEvTac NS 3.6-fold (2.4;5.5), P<0.001 NS
Collagen IVα1,
C57BL/6JBomTac a P<0.03b NS
c
Collagen IVα1, 129S6/SvEvTac NS 2.4-fold (2.1;2.8), P<0.001 16% (0;34), P = 0.04
VEGF-A, C57BL/6JBomTac NS −51% (−22;−69), P = 0.004 NS
VEGF-A, 129S6/SvEvTac NS −24% (−6;−38), P = 0.02 NS
VEGFR-2, C57BL/6JBomTac NS NS −30% (−14;−43), P = 0.002
VEGFR-2, 129S6/SvEvTac NS NS 41% (12;77), P = 0.005
Nephrin, C57BL/6JBomTac NS NS NS
Nephrin, 129S6/SvEvTac NS NS NS
Expression of mRNA measured by RT-PCR relative to 18S mRNA.
PMBL×D: interaction between diabetes and MBL.
PD: diabetic versus nondiabetic animals.
Valuesindicatediabetescomparedwithcontrol(95%conﬁdenceinterval).PMBL:MBLknockoutversusWTanimals.ValuesindicateMBLknockoutcompared
with wild-type (95% conﬁdence interval).
NS: P>0.05.
a: values could not be ﬁtted to normality and therefore Wilcoxon rank-sum tests were used to test eﬀects of diabetes and MBL.
b: P = 0.025 (WT versus diabetic WT, by Wilcoxon rank-sum tests) and P = 0.028 (MBL-KO versus diabetic MBL-KO, by Wilcoxon rank-sum test).
c: WT versus MBL-KO by Wilcoxon rank-sum test.
One diabetic WT was omitted from analyses for technical reasons.
disease in type 1 diabetes [13]. In accordance with this
observation, the MBL genotype is found to be associated
with risk of diabetic nephropathy, which may possibly
explain parts of the genetic predisposition [15, 18]. Still,
Kaunisto and colleagues did not ﬁnd the same association in
a Finnish population [16].
Speculations on alternative pathways of interaction
between MBL and diabetic kidney changes are however
unavoidable. MBL binding to human cells has been demon-
s t r a t e db yﬂ o wc y t o m e t r y[ 33]. Increasing evidence of
complement attack on self-cells in the diabetic milieu has
been reported, and, recently, MBL binding to glycated
protein and initiation of the complement system have been
demonstrated [34]. Dysfunction of complement regulation
in diabetes has also been suggested. Acosta et al. and
Qin et al. showed glycation-mediated inhibition of com-
plement regulatory protein CD59 as a possible mechanism
of growth factor release in diabetes [35, 36]. Detrimental
eﬀects of the complement system are known from studies
of ischemia-reperfusion injury, and inhibition of terminal
complement activation reduces infarct size in experimental
settings [37]. More recently, a key role of MBL in ischemia-
reperfusion injury in diﬀerent organs, including heart and
kidney, has been reported [38, 39]. In these situations,
generation of neoepitopes on cells during ischemia may
initiate complement activation. In conclusion, this study
presents data illustrating an important eﬀect of MBL on
key downstream hallmarks of diabetic kidney disease. This
eﬀect was only observed in one of the two studied mouse
strains indicating that the genetic background is important.
However, examination at several diﬀerent diabetes durations
should be made to be able to compare with the eﬀects
on early diabetic kidney changes observed in the present
study. By measurement of renal gene expression, we also
ﬁnd that the classic up-stream mediators of these changes
are unaﬀected by MBL-KO. To what extent this is caused
by inability to measure renal gene expression at the right
time of disease development is not known. Alternatively,
the existence of undiscovered pathways linking complement
and diabetic kidney disease are possible. New studies should
explore this evident connection between MBL and vascular
complications to diabetes.
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